Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Lymphoma, Large B-Cell, Diffuse 3Multiple Myeloma 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, B-Cell, Marginal Zone 2Lymphoma, B-Cell 2Recurrence 1Multi-centric Castleman's Disease 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Immunoglobulin Light-chain Amyloidosis 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1Amyloidosis 1

Interventions

Dexamethasone 16Calcium Dobesilate 9Melphalan 6Lenalidomide 6Cyclophosphamide 5Bortezomib 5pomalidomide 3venetoclax 2daratumumab 2Thalidomide 2Doxycycline 2Biopsy 24-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene 2selinexor 1pegfilgrastim 1ixazomib 1dexamethasone acetate 1dexamethasone 21-phosphate 1carfilzomib 1belantamab mafodotin 1auricularum 1Vinorelbine 1Technetium Tc 99m Pyrophosphate 1Technetium 1Tacrolimus 1Surveys and Questionnaires 1Interleukin-2 1In Situ Hybridization, Fluorescence 1In Situ Hybridization 1Hyaluronoglucosaminidase 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Amyloidosis × Hyaluronoglucosaminidase × Clear all
NCT06376214 2024-04-19

Daratumumab for Patients With Light Chain Amyloidosis

Nanjing University School of Medicine

Phase NA Recruiting
100 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡